Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection
- PMID: 17312111
- DOI: 10.4049/jimmunol.178.5.2699
Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection
Abstract
The domain III of the West Nile virus (WNV) envelope glycoprotein (E) was shown to serve as virus attachment domain to the cellular receptor, and neutralizing Abs have been mapped to this specific domain. In this study, domain III of the WNV E protein (WNV E DIII) was expressed as a recombinant protein and its potential as a subunit vaccine candidate was evaluated in BALB/C mice. Immunization of WNV E DIII protein with oligodeoxynucleotides (CpG-DNA) adjuvant by i.p. injection was conducted over a period of 3 wk. The immunized mice generated high titer of WNV-neutralizing Abs. Murine Ab against WNV E DIII protein was also capable of neutralizing Japanese encephalitis virus. The IgG isotypes generated were predominantly IgG2a in the murine sera against the recombinant protein. Splenocyte cultures from the mice coadministrated with WNV E DIII protein and CpG secreted large amounts of IFN-gamma and IL-2 and showed proliferation of T cells in the presence of WNV E DIII protein. Overall, this study highlighted that recombinant WNV E DIII protein delivered in combination with CpG adjuvant to mice generated a Th1 immune response type against WNV and can serve as a potential vaccine to prevent WNV infection.
Similar articles
-
A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII.Vaccine. 2011 Aug 26;29(37):6352-7. doi: 10.1016/j.vaccine.2011.04.116. Epub 2011 May 17. Vaccine. 2011. PMID: 21596075
-
A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.Vaccine. 2018 Mar 27;36(14):1846-1852. doi: 10.1016/j.vaccine.2018.02.073. Epub 2018 Feb 26. Vaccine. 2018. PMID: 29490880 Free PMC article.
-
A recombinant fusion protein consisting of West Nile virus envelope domain III fused in-frame with equine CD40 ligand induces antiviral immune responses in horses.Vet Microbiol. 2017 Jan;198:51-58. doi: 10.1016/j.vetmic.2016.12.008. Epub 2016 Dec 8. Vet Microbiol. 2017. PMID: 28062007
-
West Nile virus vaccines - current situation and future directions.Hum Vaccin Immunother. 2019;15(10):2337-2342. doi: 10.1080/21645515.2019.1621149. Epub 2019 Jul 10. Hum Vaccin Immunother. 2019. PMID: 31116691 Free PMC article. Review.
-
Mapping and analysis of West Nile virus-specific monoclonal antibodies: prospects for vaccine development.Expert Rev Vaccines. 2007 Apr;6(2):183-91. doi: 10.1586/14760584.6.2.183. Expert Rev Vaccines. 2007. PMID: 17408368 Review.
Cited by
-
Protective immunity to Japanese encephalitis virus associated with anti-NS1 antibodies in a mouse model.Virol J. 2012 Jul 24;9:135. doi: 10.1186/1743-422X-9-135. Virol J. 2012. PMID: 22828206 Free PMC article.
-
Pseudotyped Virus for Flaviviridae.Adv Exp Med Biol. 2023;1407:313-327. doi: 10.1007/978-981-99-0113-5_17. Adv Exp Med Biol. 2023. PMID: 36920705
-
Role of NS1 and TLR3 in Pathogenesis and Immunity of WNV.Viruses. 2019 Jul 3;11(7):603. doi: 10.3390/v11070603. Viruses. 2019. PMID: 31277274 Free PMC article.
-
A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus.PLoS One. 2011 Apr 26;6(4):e18995. doi: 10.1371/journal.pone.0018995. PLoS One. 2011. PMID: 21541326 Free PMC article.
-
Immunogenicity of a West Nile virus DIII-cholera toxin A2/B chimera after intranasal delivery.Toxins (Basel). 2014 Apr 22;6(4):1397-418. doi: 10.3390/toxins6041397. Toxins (Basel). 2014. PMID: 24759174 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical